Skip to Main Content

Paper Details

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
J Am Coll Cardiol
250
2020
ACS, Acute Coronary Syndrome, Alirocumab, LDL-, LDL-C, Lipoprotein(a), MACE, acute coronary syndrome, alirocumab, cardiovascular, cholesterol, coronary heart disease, ischemic stroke, lipoprotein(a), low-density lipoprotein cholesterol, myocardial infarction, patients, proprotein convertase subtilisin/kexin type 9, unstable angina
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital Heart & Vascular Center and Harvard Medical School
Robert A HarringtonStanford Center for Clinical Research, Stanford University
Matthew T RoeDuke Clinical Research Institute, Duke University Medical Center, Duke University School of Medicine
Sotirios TsimikasUniversity of California San Diego
  • 1 - 4

Datasets

Release 1.2